Antimicrobial Resistance in the bladder.
From our CMO Professor Scott Glickman Colleagues: In medical and surgical services spanning primary through intensive care, we are dogged...
Antimicrobial Resistance in the bladder.
UroPharma is moving rapidly to commercialisation. The science and momentum are with us.
New opportunities in bladder treatments.
Better bladder treatments in the pipeline
New Bladder therapies to ease the suffering of millions by simply changing clinical practice.
86% nocturia reduction in Direct-to-Bladder clinical trial.
Benefits of Direct-to-Bladder drug targeting.
Current bladder therapies is causing harm to millions of people daily
Direct to Bladder Therapies
UTI update
New Anglia Local Enterprise Partnership - Certificate of Support
Feasibility study of targeted drug delivery product to the bladder
GMDN Agency welcomes UK-wide Medical Device Information System
MS Patients at Higher Risk of Bladder Cancer, But Not Breast, Colorectal Cancer
UK set to approve Pfizer-BioNTech Covid vaccine within days
Covid-19: Normal life back next winter, says vaccine creator
Claiming Equivalence Under the EU MDR
NICE draft guidance recommends siponimod for treating secondary progressive multiple sclerosis
Placing medical devices on the UK market after the end of Brexit transition
Test can help urologists rule out bladder cancer in two hours